KDIGO conference report on heart failure with CKD: SGLT2 inhibitors, RAAS inhibitors, finerenone and GLP-1 receptor agonists may benefit both, though advanced CKD evidence is limited; small eGFR falls after starting HF therapy generally need not stop it.
Guideline
Lam et al. Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference